RTP Mobile Logo
Oncology Today with Dr Neil Love: Ocular Toxicities in Patients Receiving Anticancer Therapy (Video Lecture)
Released September 2022

Featuring a slide presentation and related discussion from Dr Asim Farooq. Published September 6, 2022. (Video Lecture)

CE Information and Faculty Disclosures

    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of ocular toxicities associated with anticancer therapies.


    • Appreciate the pathophysiology, frequency and severity of ocular toxicities associated with the administration of specific anticancer therapies for various solid tumors and hematologic cancers.
    • Recall strategies commonly employed to identify ocular toxicities in individuals receiving anticancer treatment, and use this information to appropriately intervene in patients for whom these side effects are suspected or diagnosed.
    • Understand the incidence of ocular toxicities observed in pivotal trials evaluating novel agents and strategies demonstrating efficacy in the management of patients with various tumor types, and educate individuals about to commence therapy with these approaches regarding the potential development of these adverse events and what to do if they are suspected.
    • Appraise the role of multidisciplinary specialists such as ophthalmologists and other eye-care professionals in the diagnosis and management of ocular toxicities, and effectively collaborate with these clinicians to offer best-practice care for patients at high-risk for or with a suspected or confirmed diagnosis of these toxicities.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Presentation Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Asim V Farooq, MD
    Associate Professor
    Vice Chair for Academic Affairs
    Director of Medical Student Education
    Department of Ophthalmology and Visual Science
    The University of Chicago Medical Center
    Chicago, Illinois

    Consulting Agreements: Ambrx, Amgen Inc, Eisai Inc, GlaxoSmithKline, Sanofi Genzyme, Seagen Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    These activities are supported by educational grants from Genmab and Seagen Inc, GlaxoSmithKline, ImmunoGen Inc, and Incyte Corporation.

    Release date: September 2022
    Expiration date: September 2023

Acknowledge and close

Watch video
(WIFI is recommended for best performance):